Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition

Metabolism

Oral

Body

Tuesday, 12 May 2026

Hall 1A

16:00 - 17:50

Moderators: Irene Vavasour & Ladislav Valkovič

Session Number: 401-04

No CME/CE Credit

Similar Sessions

This oral session highlights emerging quantitative MR and metabolomic approaches that probe tissue-specific and whole-body metabolism, spanning technical innovation, disease mechanisms, and metabolic responses to therapy and intervention.

Skill Level: Intermediate

16:00		401-04-001. Metabolism in the Body Ladislav Valkovič Oxford Centre for Clinical MR Research (OCMR), University of Oxford, Oxford, United Kingdom
16:11		401-04-002. Decoding Tumor-Specific Metabolic Rewiring in Prostate Cancer through ¹H NMR Metabolomics Shivalika Bahukhandi, RAJEEV Kumar, Seema Kaushal, Maroof Khan, Virendra Kumar All India Institute of Medical Sciences, New Delhi, India Impact: The study reveals a unique tumor-specific metabolic signature of PCa, highlighting pathways involved in membrane synthesis, methylation, and signalling. These findings may enhance understanding of tumor metabolism, guiding biomarker discovery and metabolic-targeted therapies.
16:22		401-04-003. Direct dynamic 2H MRSI and metabolic modelling for 3D characterization of glucose oxidative metabolism in rats brain Alessio Siviglia, Brayan Alves, Thanh Phong Lê, Cristina Cudalbu, Bernard Lanz CIBM Center for Biomedical Imaging, Lausanne, Switzerland Impact: This study establishes a metabolic modelling empowered 3D ²H-MRSI approach for in-vivo dynamic mapping of regional oxidative glucose metabolism. The protocol integration with 3D-¹H-FID-MRSI acquisitions allows for real-time pool size measurement, providing accurate metabolism kinetics characterization.
16:33		401-04-004. Hyperpolarized 13C Pyruvate MRI: Quantifying Glycolytic Hypermetabolism for Viability Assessment Post-Myocardial Infarction Esben Hansen, Nikolaj Bøgh, Jakob Lindhardt, Rasmus Tougaard, Won Kim, Christoffer Laustsen Aarhus University, Aarhus, Denmark Impact: This work validates cardiac metabolic MRI - for quantifying metabolic viability in the moving heart. HP-MRI offers a unique, non-invasive biomarker distinct from conventional structural imaging, which is essential for the development and monitoring of metabolic therapies for reperfusion injury.
16:44		401-04-005. Cancer treatment-induced cardiotoxicity detection and cardioprotection Monitoring from SGLT2i using multimodal MR biomarkers Donghyun Hong, Yoo Jin Hong, Xiao Ji, Manushka Vaidya, Umesh Masharani, George Brooks, Avantika Sinha, Renuka Sriram, Dan Vigneron, Roselle Abraham, Peder Larson University Of California, San Francisco (UCSF), United States of America Impact: Integrated ¹H CINE MRI, ³¹P MRS, and hyperpolarized ¹³C MRI enable early detection of chemotherapy-induced cardiotoxicity and assessment of SGLT2 inhibitor cardioprotection, revealing metabolic and energetic remodeling that precedes functional decline and providing a translational framework for clinical cardiotoxicity monitoring.
16:55		401-04-006. Quantify TAVR Relieved Metabolic Stress in Aortic Stenosis Patients using Noninvasive Coronary Sinus Oximetry by CMR Chia Chi Yang, Henghui Zhang, Li-Ting Huang, Ranran Zhang, Archana Malagi, Yuheng Huang, Xinheng Zhang, Hsu-Lei Lee, George Thornton, Hasanian Al-Jilaihawi, Xiaoming Bi, Chang Gao, Debiao Li, Guan Wang, Hsin-Jung Yang Cedars-Sinai Medical Center, Los Angeles, United States of America Impact: By our approach, the oxygen metabolism in AS patients can be quantified, which provides us with a chance for improving risk stratification and patient management.
17:06		401-04-007. 23Na-MRI and 1H-MRI to quantify the magnitude and time course of muscle disruption after high-load eccentric contractions Ben Prestwich, Charles Steward, Theodora Slater, Abhishek Sheth, Joanne Mallinson, Paul Greenhaff, Susan Francis University of Nottingham, Nottingham, United Kingdom Impact: ²³Na MRI and ¹H T₂ mapping allowed non-invasive quantification of the magnitude and time-course of muscle disruption and recovery following eccentric muscle contractions in volunteers. This was markedly slower than serum creatine kinase concentration recovery (systemic muscle disruption marker).
17:17		401-04-008. Early sarcopenia risk identification in cirrhotic patients using 31P-MRS skeletal muscle metabolism on a clinical MRI system Jihun Kwon, Kumi Ozaki, Yasutomo Katsumata, Naoki Oishi, Yukichi Tanahashi, Marc Van Cauteren, Satoshi Goshima Philips Japan, Tokyo, Japan Impact: Dynamic muscle ³¹P-MRS findings showed impairment in fast-twitch myofiber energy metabolism in cirrhotic patients with poor liver reserve capacity. This motivates further studies to determine if the ³¹P-MRS findings might help identifying cirrhotic patients at risk of developing sarcopenia early.
17:28		401-04-009. MRI/S reveals metabolic changes in muscle, liver, and fat after 3-month complex lifestyle intervention in obese adults Radka Klepochová, Lucia Slobodová, Ivica Just, Petronela Forišek Paulová, Oksana Mytiai, Ali Amiri, Petra Vadovičová, Jana Kubíčková, Daria Barková, Patrik Konrády, Viera Litváková, Peter Minárik, Pavol Szomolanyi, Martin Krssak, Jozef Ukropec, Barbara Ukropcová Clinical Division of Internal Medicine III, Vienna, Austria Impact: This study demonstrates the power of combined multi-organ MRI/MRS to non-invasively monitor metabolic adaptations to lifestyle intervention in obesity, providing novel biomarkers of improved lipid metabolism and mitochondrial function that may guide personalized obesity management and metabolic health strategies.
17:39		401-04-010. NMR-Based Metabolomics Analysis of Diabetes-Associated Metabolic Dysregulation in Early-Stage Chronic Kidney Disease Upasna Gupta, Amrita Sahu, Anupama Kaul, Jiya Mishra, Subash Yadav, Manas Behera, Bikash Baishya, Neeraj Sinha Centre of Biomedical Research, Lucknow, India Impact: This study reveals early metabolic dysregulation in CKD, exacerbated by diabetes, highlighting key biomarkers and pathways. Findings enable improved risk stratification, targeted interventions, and precision therapies, advancing early diagnosis and personalized management to slow CKD progression and prevent complications.